NK-92; Natural Killer Cell; Human (Homo sapiens) Item ID: ATCCRL2407
| Permits and Restrictions |
View Permits View Restrictions |
|---|---|
| Organism | Homo sapiens, human |
| Tissue | peripheral blood |
| Cell Type | natural killer cell; NK cell |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension, multicell aggregates |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | malignant non-Hodgkin's lymphoma |
| Age | 50 years |
| Gender | male |
| Ethnicity | Caucasian |
| Applications | This cell line is a suitable transfection host.The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays.NK-92 cells (after irradiation to prevent proliferation) can be used effectively for immunological ex vivo purging of leukemia from blood without compromising hematopoietic cell function. |
| Storage Conditions | liquid nitrogen vapor phase |
| Images | |
|---|---|
| Derivation | NK-92 is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma. |
| Clinical Data | 50 years Caucasian, White male |
| Antigen Expression | CD2 +, CD7 +, CD11a +, CD28 + , CD45 +, CD54 +, CD56 +, CD1 -, CD3 -, CD4 -, CD5 -, CD8 -, CD10 -, CD14 -, CD16 -, CD19 -, CD20 -, CD23 -, CD34 -, HLA-DR - |
| Comments |
The cell line is dependent on the presence of recombinant Il-2 and a dose as low as 10 U/mL is sufficient to maintain proliferation; cells will die within 72 hours in the absence of IL-2.
NK-92 cells have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR. ATCC confirmed this cell line is positive for the presence of Epstein-Barr viral DNA sequences via PCR. |
| Complete Growth Medium | The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; 100-200 U/ml recombinant IL-2; adjust to a final concentration of 12.5% horse serum and 12.5% fetal bovine serum. |
|---|---|
| Subculturing |
Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 2 to 3 X 105 viable cells/mL. These cells tend to grow in aggregates that may lose viability when they are dispersed. Accurate counts and viabilities may not be possible. Corning® T-75 flasks (catalog #431464) are recommended for subculturing this product. NK-92 cells are extremely sensitive to overgrowth and media exhaustion. Medium Renewal: Replace with fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation | Freeze medium: 50% FBS; 40% complete growth medium ; 10% DMSO. Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C Growth Conditions: Successful growth of this cell line is very dependent upon the quality of IL-2 used in the growth medium. ATCC recommends using the highest quality IL-2 available. |
| STR Profile | Amelogenin: X,Y CSF1PO: 11,12 D13S317: 9,12 D16S539: 11,12 D5S818: 12,13 D7S820: 10,11 THO1: 6,9.3 TPOX: 8 vWA: 18 |
|---|
| Name of Depositor | NantKwest Inc. |
|---|---|
| References |
Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260 Klingemann HG, et al. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transplant. 2: 68-75, 1996. PubMed: 9118301 Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666 Klingemann HG, Miyagawa B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 87: 4913-1914, 1996. PubMed: 8639869 Komatsu F, Kajiwara M. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol. Res. 10: 483-489, 1998. PubMed: 10338151 Yan Y, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 4: 2859-2868, 1998. PubMed: 9829753 Maki G, et al. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 12: 1565-1572, 1998. PubMed: 9766501 Nagashima S, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861, 1998. PubMed: 9573023 Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052 |